We Make Tregs, Better

About GentiBio

At GentiBio, we understand that a balanced immune system is paramount to health and wellness. Certain diseases can turn the immune system against itself, causing the body to attack its own cells and tissues. Regulatory T cells, or Tregs, play a central role in keeping the immune system in check by applying the brakes to runaway or maladaptive immune responses.

Combining insights from Tregs biology and antigen receptor engineering, our cell therapies are equipped with the key properties needed to successfully restore immune tolerance in the body and overcome the major limitations in existing Tregs cell-based therapeutics. We are at the forefront of leveraging a unique therapeutic modality that directly addresses the underlying cause of autoimmune, alloimmune, autoinflammatory and allergic diseases.

Our Approach

Malfunctioning Tregs are central to many debilitating autoimmune diseases. Available treatment options often have systemic effects on the body and can indiscriminately suppress the entire immune system, weakening its ability to fight harmful invaders like viruses and potentially cancerous cells. GentiBio’s approach leverages precise targeting technology to direct potent engineered Tregs, or EngTregs to the specific tissues afflicted with the aberrant immune responses.

Our EngTregs:

Are scalable… Rather than isolating Tregs – a very rare population in the blood, we zero in on more abundant effector T cells to generate our EngTregs. Our technology stably converts the effector T cells into EngTregs and ensures our ability to scale manufacturing at very efficient costs.

Have a potent and durable effect… Once deployed to their target tissues, our EngTregs suppress the T cells that are actively attacking the body through a variety of mechanisms. Extensive studies show that Tregs remain in the body for months and even years potentially providing an avenue to reset the immune system after limited dosing. Similarly, EngTregs are stable, potent and precise enough to prevent the immune system from turning against itself in select tissues, while allowing the body to continue to respond to other threats such as infections and cancer.

Can be efficiently expanded and controlled after administration… We employ a fine-tuning system that can be used to tailor the performance and durability of EngTregs in the body to the needs of the patient.

Leadership

We are a team of seasoned and passionate leaders, scientists and experts in the burgeoning and rapidly expanding Tregs therapeutic space. We believe that the time has arrived to fully harness the therapeutic potential of Tregs. We are committed to unleashing the full potential of engineered Tregs to develop transformative treatments for autoimmune, alloimmune, autoinflammatory and allergic disorders.

Chandra Patel, Ph.D.
Co-founder and Vice President, R&D Operations
David Rawlings, M.D.
Scientific Co-founder, Senior Scientific Advisor
Catherine Thut, Ph.D., MBA
Chief Business Officer
Andy Walker, Ph.D.
Co-founder and Chief Technology Officer
Tom Wickham, Ph.D.
Chief Scientific Officer
Adel Nada, M.D., M.S.
Co-founder, President, Chief Executive Officer and Director
Jane Buckner, M.D.
President, Benaroya Research Institute and Scientific Co-Founder
Gideon Gross, Ph.D.
Associate Professor & PI, MIGAL and Scientific Co-Founder
Amy Jennings, Ph.D.
Principal, RegPath Consulting
Stanford Peng, M.D., Ph.D.
President, R&D, Alpine Immune Sciences
David Rawlings, M.D.
Director, Center for Immunity and Immunotherapies, Seattle Children’s Research Institute and Scientific Co-founder and Senior Scientific Advisor
Andrew Scharenberg, M.D.
Scientific co-founder; SAB Chair; CEO, Umoja Biopharma
Hadas Weinstein-Marom, Ph.D.
Senior Scientist & Lecturer, MIGAL, Scientific Co-Founder
Roy Amariglio, Ph.D.
Principal, OrbiMed
Nathaniel Brooks Horwitz
Venture Associate,
RA Capital Management
Erez Chimovits, MBA
Partner, OrbiMed
Carl L. Gordon, Ph.D., CFA
Director, Managing
Partner, OrbiMed
Andrew Levin, Ph.D., M.D.
Managing Director,
RA Capital Management
Adel Nada, M.D., M.S.
President and Chief Executive Officer, GentiBio
Brian Phillips, Ph.D.
Director, Intellectual Property Core, Seattle Children’s Research Institute
Nandita Shangari, Ph.D.
Principal, Novartis Venture Fund
Michal Silverberg, MBA
Managing Director,
Novartis Venture Fund
Senior Management
Chandra Patel, Ph.D.
Co-founder and Vice President, R&D Operations
David Rawlings, M.D.
Scientific Co-founder, Senior Scientific Advisor
Catherine Thut, Ph.D., MBA
Chief Business Officer
Andy Walker, Ph.D.
Co-founder and Chief Technology Officer
Tom Wickham, Ph.D.
Chief Scientific Officer
Adel Nada, M.D., M.S.
Co-founder, President, Chief Executive Officer and Director
Scientific Advisory Board
Jane Buckner, M.D.
President, Benaroya Research Institute and Scientific Co-Founder
Gideon Gross, Ph.D.
Associate Professor & PI, MIGAL and Scientific Co-Founder
Amy Jennings, Ph.D.
Principal, RegPath Consulting
Stanford Peng, M.D., Ph.D.
President, R&D, Alpine Immune Sciences
David Rawlings, M.D.
Director, Center for Immunity and Immunotherapies, Seattle Children’s Research Institute and Scientific Co-founder and Senior Scientific Advisor
Andrew Scharenberg, M.D.
Scientific co-founder; SAB Chair; CEO, Umoja Biopharma
Hadas Weinstein-Marom, Ph.D.
Senior Scientist & Lecturer, MIGAL, Scientific Co-Founder
Board of Directors
Roy Amariglio, Ph.D.
Principal, OrbiMed
Nathaniel Brooks Horwitz
Venture Associate,
RA Capital Management
Erez Chimovits, MBA
Partner, OrbiMed
Carl L. Gordon, Ph.D., CFA
Director, Managing
Partner, OrbiMed
Andrew Levin, Ph.D., M.D.
Managing Director,
RA Capital Management
Adel Nada, M.D., M.S.
President and Chief Executive Officer, GentiBio
Brian Phillips, Ph.D.
Director, Intellectual Property Core, Seattle Children’s Research Institute
Nandita Shangari, Ph.D.
Principal, Novartis Venture Fund
Michal Silverberg, MBA
Managing Director,
Novartis Venture Fund